安徽医科大学第一附属医院肿瘤内科;
目的 探讨晚期胆胰肿瘤患者在真实世界中接受一线或二线抗肿瘤治疗时，应用糖类抗原19-9(CA19-9)下降动力学预测近期疗效、判断生存预后的价值。方法 回顾性收集晚期胆胰来源腺癌患者89例，记录不同时间节点和不同下降幅度的CA19-9动力学数据。评估其与患者临床病理特征、接受抗肿瘤治疗近期疗效和生存预后的关系。结果 纳入患者基线CA19-9水平为1.20～65 706.40 U/ml,中位值是303.11 U/ml。基线CA19-9水平与性别、年龄、体质量指数、原发肿瘤部位、肝转移、肺转移、淋巴结转移、腹腔腹膜转移、体力状态评分、治疗线数和治疗方式均无统计学关联。患者基线CA19-9与系统免疫炎症指数、预后营养指数和总胆红素也无显著相关性。治疗2～3程后CA19-9下降达25%或50%时，预示患者可以获得肿瘤客观缓解或疾病控制的近期疗效。治疗方式选择多类型药物联合以及1程治疗后CA19-9下降达25%是患者接受一或二线治疗获得较长无进展生存时间的独立预后因素。结论 CA19-9下降动力学在预测晚期胆胰肿瘤治疗疗效和生存预后中具有一定的价值。
| 76 | 0 | 12 |
| 下载次数 | 被引频次 | 阅读次数 |
[1] 郑荣寿，陈茹，韩冰峰，等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2024,46(3):221-31.doi:10.3760/cma.j.cn112152-20240119-00035.[1] Zheng R S,Chen R,Han B F,et al.Cancer incidence and mortality in China,2022[J].Chin J Oncol,2024,46(3):221-31.doi:10.3760/cma.j.cn112152-20240119-00035.
[2] Wang Y,Li J,Xia Y,et al.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J].J Clin Oncol,2013,31(9):1188-95.doi:10.1200/JCO.2012.41.5984.
[3] Haas M,Heinemann V,Kullmann F,et al.Prognostic value of CA 19-9,CEA,CRP,LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer:results from a multicenter,pooled analysis of patients receiving palliative chemotherapy[J].J Cancer Res Clin Oncol,2013,139(4):681-9.doi:10.1007/s00432-012-1371-3.
[4] Chen Y,Shao Z,Chen W,et al.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer[J].Oncotarget,2017,8(18):29925-34.doi:10.18632/oncotarget.15557.
[5] Colloca G A,Venturino A,Guarneri D.Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy:a retrospective analysis[J].Pancreatology,2020,20(6):1189-94.doi:10.1016/j.pan.2020.07.397.
[6] Wainberg Z A,Melisi D,Macarulla T,et al.NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3):a randomised,open-label,phase 3 trial[J].Lancet,2023,402(10409):1272-81.doi:10.1016/S0140-6736(23)01366-1.
[7] Takahara N,Nakai Y,Isayama H,et al.CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer[J].Cancer Chemother Pharmacol,2017,80(6):1105-12.doi:10.1007/s00280-017-3456-9.
[8] Lee B S,Lee S H,Son J H,et al.Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma[J].J Gastroenterol Hepatol,2016,31(2):493-500.doi:10.1111/jgh.13059.
[9] Huang G,Xi P,Yao Z,et al.The clinical association between the inflammation-nutritional condition and prognosis of locally advanced intrahepatic cholangiocarcinoma after R0 resection:evidence from competing risk and propensity matching analysis[J].J Inflamm Res,2024,17:2787-99.doi:10.2147/JIR.S460103.
[10] Lu J N,Zhou L S,Zhang S,et al.Performance of nutritional and inflammatory markers in patients with pancreatic cancer[J].World J Clin Oncol,2024,15(8):1021-32.doi:10.5306/wjco.v15.i8.1021.
[11] Yang Z,Zhang D,Zeng H,et al.Inflammation-based scores predict responses to PD-1 inhibitor treatment in intrahepatic cholangiocarcinoma[J].J Inflamm Res,2022,15:5721-31.doi:10.2147/JIR.S385921.
[12] Sun Y,Hu J,Wang R,et al.Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy[J].Cancer Med,2024,13(13):e7453.doi:10.1002/cam4.7453.
基本信息:
DOI：10.19405/j.cnki.issn1000-1492.2025.04.018
中图分类号:R735.9;R735.8
引用信息:
[1]张逸寅,戴映,何子然等.糖类抗原19-9下降动力学在晚期胆胰肿瘤中的应用价值[J].安徽医科大学学报,2025,60(04):712-718.DOI:10.19405/j.cnki.issn1000-1492.2025.04.018.
基金信息:
安徽省自然科学基金项目(编号：2008085QH424); 安徽省高校自然科学研究重点项目(编号：2024AH050816); 安徽医科大学基础与临床提升计划项目(编号：2023xkjT039)~~